603 related articles for article (PubMed ID: 31582717)
1. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report.
Fontana F; Alfano G; Bardhushi E; Ligabue G; Giovanella S; Neri I; Cappelli G
Am J Case Rep; 2019 Oct; 20():1460-1465. PubMed ID: 31582717
[TBL] [Abstract][Full Text] [Related]
2. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
Cao M; Leite BN; Ferreiro T; Calvo M; Fernández C; Alonso Á; Rodriguez A; Salvador P; Seijo R; Pita S; Arjona E; Rodríguez de Córdoba S; Valdés Cañedo F
Am J Nephrol; 2018; 48(3):225-233. PubMed ID: 30205388
[TBL] [Abstract][Full Text] [Related]
3. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
[TBL] [Abstract][Full Text] [Related]
5. A life-threatening case of pregnancy-related atypical Haemolytic uremic syndrome and successful treatment with Eculizumab.
Puri P; Hanxhiu A; O'Hara DV; Hsu D; Vucak-Dzumhur M
BMC Nephrol; 2020 Nov; 21(1):488. PubMed ID: 33203373
[TBL] [Abstract][Full Text] [Related]
6. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.
Huerta A; Arjona E; Portoles J; Lopez-Sanchez P; Rabasco C; Espinosa M; Cavero T; Blasco M; Cao M; Manrique J; Cabello-Chavez V; Suñer M; Heras M; Fulladosa X; Belmar L; Sempere A; Peralta C; Castillo L; Arnau A; Praga M; Rodriguez de Cordoba S
Kidney Int; 2018 Feb; 93(2):450-459. PubMed ID: 28911789
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: A Systematic Review.
Gupta M; Govindappagari S; Burwick RM
Obstet Gynecol; 2020 Jan; 135(1):46-58. PubMed ID: 31809447
[TBL] [Abstract][Full Text] [Related]
9. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
[TBL] [Abstract][Full Text] [Related]
10. [HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review].
Mancini A; Ardissino G; Angelini P; Giancaspro V; La Raia E; Nisi M; Proscia A; Tarantino G; Vitale O; D'elia F
G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983177
[TBL] [Abstract][Full Text] [Related]
11. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
[TBL] [Abstract][Full Text] [Related]
12. Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era.
Avila Bernabeu AI; Cavero Escribano T; Cao Vilarino M
Nephron; 2020; 144(11):537-549. PubMed ID: 32950988
[TBL] [Abstract][Full Text] [Related]
13. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
Kant S; Bhalla A; Alasfar S; Alachkar N
BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487
[TBL] [Abstract][Full Text] [Related]
14. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
Olson SR; Lu E; Sulpizio E; Shatzel JJ; Rueda JF; DeLoughery TG
Am J Nephrol; 2018; 48(2):96-107. PubMed ID: 30110670
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.
Kim MJ; Lee H; Kim YH; Jin SY; Kim HJ; Oh D; Jeon JS
BMC Nephrol; 2021 Mar; 22(1):86. PubMed ID: 33691638
[TBL] [Abstract][Full Text] [Related]
17. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
Asif A; Nayer A; Haas CS
J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
19. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.
Cavero T; Arjona E; Soto K; Caravaca-Fontán F; Rabasco C; Bravo L; de la Cerda F; Martín N; Blasco M; Ávila A; Huerta A; Cabello V; Jarque A; Alcázar C; Fulladosa X; Carbayo J; Anaya S; Cobelo C; Ramos N; Iglesias E; Baltar J; Martínez-Gallardo R; Pérez L; Morales E; González R; Macía M; Draibe J; Pallardó L; Quintana LF; Espinosa M; Barros X; Pereira F; Cao M; Moreno JA; Rodríguez de Córdoba S; Praga M;
Kidney Int; 2019 Oct; 96(4):995-1004. PubMed ID: 31420192
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
